© 2021 BioMarin. All rights reserved.

Back to Pipeline

BMN 307 is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy designed to normalize blood phenylalanine (Phe) concentration levels in patients with PKU.

BMN 307 represents a potential third PKU treatment option from BioMarin, and our second gene therapy clinical program. Both the FDA and European Medicines Agency have granted BMN 307 Orphan Status. BMN 307 has not been determined to be safe or effective and is not approved for use.


Molecule
Phase (Preclinical, Phase 1, Phase 2, Phase 3, BLA/NDA/MAA, Approval)
  • BMN 307 AAV
    Gene Therapy
    Phase 1
    Target Indication

    BMN 307 is an AAV5-phenylalanine hydroxylase (PAH) gene therapy under investigation to determine if it can normalize blood phenylalanine concentration levels in patients with PKU.

    Learn More

Image: BioMarin scientists
Clinical Trials

More than 20 years of proven clinical success.

Our thoughtful approach to clinical trial design enables us to move fast and efficiently while protecting the safety of our patients.

Learn More about our clinical trials